AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02618135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology.
Study NCT02618135 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Participants will wait for 8 weeks before training intervention begins.~Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology.
Study NCT00977886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, 10 days
Study NCT00977886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELB353
Description: Oral, 10 days
Study NCT01517373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days
Study NCT01517373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 10 mg
Description: Combination of tablets and capsules, dose of 10 mg, a total of 3 pills/dose, administered once daily for 84-days
Study NCT01517373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 50 mg
Description: Combination of tablets and capsules, dose of 50 mg, a total of 3 pills/dose, administered once daily for 84-days
Study NCT01517373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 100 mg
Description: Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days
Study NCT01517373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days
Study NCT03323437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Participants will meet with a study doctor physician once per week (about 3 times total) to monitor progress and side-effects of risperidone, which includes taking 4 assessments each time. After 4 weeks of taking Risperidone, participant will be assessed and scanned with the MRI/MRS scanner again.
Study NCT01534351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Finasteride 5 mg oral tablet taken once daily.
Study NCT01534351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin 0.2 mg oral capsule taken once daily.
Study NCT01534351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Tamsulosin 0.2 mg oral capsule taken once daily.
Study NCT01534351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride-matching placebo
Description: Matching placebo to finasteride 5 mg oral tablet taken once daily.
Study NCT01534351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin-matching placebo
Description: Matching placebo to tamsulosin 0.2 mg oral capsule taken once daily.
Study NCT02182778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin
Description: Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
Study NCT02182778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin /S-1
Description: S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
Study NCT00566371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Description: Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
Study NCT00566371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT05431231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Session Alliance Inventory - for patient
Description: this questionnaire has two versions, one for patients and one for the main therapist in the therapeutic team, and its goal is to evaluate the therapist-patient relationship (therapeutic alliance). It is composed of 6 statements that relate to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). In the current study, patients will define who their main therapist is. Falkenstrom et al. reported that in their three tested samples, the alpha coefficients ranged from 0.89 to 0.94.
Study NCT04325711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSPCHA131
Description: CSPCHA131 will be administered twice weekly in the first three weeks of a 4-week cycle.
Study NCT03367338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-phosphate diet
Description: Very low-phosphate diet, PPR value of 8 mg/g, vs. low-phosphate diet, PPR value of 10 mg/g
Study NCT04257487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulodexide
Description: 2 soft capsules of Vessel® 250 LSU BID for 12 months
Study NCT04257487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulodexide and placebo
Description: 1 soft capsule of Vessel® 250 LSU and 1 soft capsule of placebo BID for 12 months
Study NCT04257487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic sulodexide 250 LSU
Study NCT01206660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desoximetasone Spray 0.25%
Description: Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
Study NCT01206660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered to affected area twice a day for 28 days
Study NCT04767932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vibration machine
Description: Experimental: vibration intervention the experimental group will perform 20mins/ section, three times weekly for 8 weeks vibration training
Study NCT01811654 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-Articular Hyaluronic Acid-Euflexxa
Description: IAHA was approved by the FDA in 1997 as a synovial fluid replacement device to help relieve the pain associated with knee osteoarthritis (OA) in patients who fail to respond adequately to conservative treatment and simple analgesics. In this study, IAHA, specifically Euflexxa, will be used off-label to determine whether patients afflicted with PFPS will experience similar analgesic effects as seen in those with OA.
Study NCT02575495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7 days course of antibiotic treatment
Description: start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 7 days
Study NCT02575495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14 days course of antibiotic treatment
Description: start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 14 days
Study NCT03449563 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Open TPVB
Description: In Group E,the thoracic paravertebral block was performed under the direct vision with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
Study NCT05431231 — intervention group
Intervention type: OTHER
Intervention: Quality of service/satisfaction questionnaire
Description: measured by the quality of service department at Sheba Medical Health Center (or - PROMS, to be decided). Here customer's experience of the online services would be measured as well.
Study NCT05431231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical decision-making style
Description: a questionnaire with two - patient and therapist - versions, meant to evaluate decision making style. It was developed by Puschner, Neumann, Jordan, et al. in 2013. The questionnaire constitutes a modified version of the Autonomy Preference Index (API), which was developed by Ende, Kazis, Ash, \& Moskowitz in 1989 for mental health patients. In the current study, only the therapist/psychiatrist version would be administered. The questionnaire is composed of 21 items and yields two components related to clinical decision making: preferences in decision making style and information seeking during decision making. Puschner et al (2013) reported that Kronbach's α coefficient ranged from 0.87 to 0.89.
Study NCT03449563 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided TPVB
Description: In Group U, thoracic paravertebral block was performed on the operated side under ultrasound guidance with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
Study NCT03449563 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: In Group G,patients were just received Patient-controlled intravenous analgesia after the surgery.
Study NCT00442494 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: intravenous hydrocortisone
Study NCT01732029 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normobaric hypoxia chamber
Study NCT02889497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the first batch vaccine
Study NCT02889497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the second batch vaccine
Study NCT02889497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the third batch vaccine
Study NCT05431231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Global Assessment of Functioning Scale
Description: a questionnaire meant to assess the patient's global functioning. It was developed by Jones, Thornicroft, Coffey, \& Dunn in 1996. The GAF was used in DSM-IV as the fifth axis of psychiatric evaluation. The therapist is asked to determine for each patient a general score ranging from 10 to 100 to describe his everyday functioning in psychological, social and occupational fields. A score of 10 refers to a state of persistent danger of severely hurting the self or others, and a score of 100 refers to superior functioning in all areas of life. Jones et al. reported that Kronbach's α ranged from 0.74 to 0.76.
Study NCT06532929 — intervention group
Intervention type: DEVICE
Intervention: Orthopaedic surgeries (ankle)
Description: ankle lateral ligament reconstruction in ligamentoplasty procedures
Study NCT05431231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Session Alliance Inventory - for therapist
Description: a questionnaire that has two - patient and therapist - versions, meant to assess the therapist-patient relationship (therapeutic alliance). It was developed by Falkenstrom, Hatcher, Skjulsvik, Larsson, \& Holmqvist in 2014. Each questionnaire (patient/therapist) is composed of 6 statements that refer to the therapeutic relationship. The participants are asked to rate the extent to which the statements describe their experience accurately using a 7-level Likert scale (1 - does not describe my experience in any way, 7 - describes my experience exactly). Falkenstrom et al reported that Kronbach's α coefficient ranged from 0.89 to 0.94 for their three tested samples. In the current study, patients will define who their main therapist is.
Study NCT02196090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention
Description: A procedure where patients with OCD test out their fears without responding by compulsive act.
Study NCT04257487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic sulodexide 250 LSU
Study NCT02691169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: 18F-DCFPyL is a sterile diagnostic radiopharmaceutical used for PET imaging.
Study NCT02196090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold face gel mask
Description: Temporary application of cold eye mask on the face is commonly used for relaxation purpose.
Study NCT03012360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftriaxone
Description: 2 g iv every 24h
Study NCT03012360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Description: 400 mg iv every 8h
Study NCT03012360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imipenem
Description: 1 g iv every 8h
Study NCT03012360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linezolid
Description: 600 mg iv every 12h
Study NCT03012360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: The SSI 0.9% or dextrose 5% used are based on routine procedure in different participating centers.Placebo will be prepared using IV bags, with the same of quantity as IMP
Study NCT03012360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The SSI 0.9% or dextrose 5% used are based on routine procedure in different participating centers.Placebo will be prepared using IV bags, with the same of quantity as IMP
Study NCT04069624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOUD Pre-Treatment Telehealth
Description: Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth
Study NCT04069624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOUD Pre-Treatment Telehealth and Peer Navigator
Description: Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth. Additionally, participants will be connected with a Peer Navigator who will meet with them via telehealth prior to release and provide ongoing support by telephone post-release.
Study NCT04069624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Medications to treat opioid use disorder (MOUD) pre-treatment.
Study NCT04816370 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FSFI
Description: 2 group and 2 subgroup
Study NCT04655690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0471-0119
Description: Participants will be randomised to either of five dose levels 0.3, 0.6, 1.2, 2.4 or 3.6 of NNC0471-0119 nanomol per kilogram body weight, which will be administered as a single dose. NNC0471-0119 will be administered subcutaneously (s.c., under the skin) in fasting state.
Study NCT04655690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fast-acting insulin aspart
Description: Participants will get a fixed dose of 0.2 units of fast-acting insulin aspart (Fiasp®) per kilogram body weight, administered subcutaneously (s.c., under the skin) in fasting state.
Study NCT02182999 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wound infiltration catheter
Description: Wound catheter with multiple and laterally aligned holes is inserted through the intact skin via an 16G iv catheter 2 cm proximal-laterally from the proximal end of the dorsomedial skin incision and placed subcutaneously through the wound and medially around the first metatarsal so that the tip projects into the interdigital space 1/2.
Study NCT02182999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration catheter
Description: Wound catheter with multiple and laterally aligned holes is inserted through the intact skin via an 16G iv catheter 2 cm proximal-laterally from the proximal end of the dorsomedial skin incision and placed subcutaneously through the wound and medially around the first metatarsal so that the tip projects into the interdigital space 1/2.
Study NCT02182999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: The catheter is connected to the perfusor line filled with saline 0.9% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
Study NCT02182999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2%
Description: The catheter is connected to the perfusor line filled with Ropivacaine 0.2% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
Study NCT03598660 — intervention group
Intervention type: GENETIC
Intervention: Sorcin gene expression
Description: Sorcin gene expression Will be measured by real time PCR
Study NCT03598660 — intervention group
Intervention type: OTHER
Intervention: Annexin A3 serum mesurement
Description: serum mesurement of Annexin A3 by enzyme linked immuno sorbent assay (ELISA)
Study NCT01666990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TwHF
Description: Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
Study NCT06532929 — intervention group
Intervention type: DEVICE
Intervention: Orthopaedic surgeries (shoulder)
Description: rotator cuff repair
Study NCT06532929 — intervention group
Intervention type: DEVICE
Intervention: Orthopaedic surgeries (knee)
Description: knee cruciate ligaments reconstruction in ligamentoplasty procedures
Study NCT01666990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
Study NCT00500669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betadine
Description: Topically
Study NCT00500669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betadine
Description: Topically
Study NCT03352869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Use Exenatide for 3 months to treat PCOS
Study NCT02671552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Protein-Type A Microspheres
Description: Given IV
Study NCT03352869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Use Metformin for 3 months to treat PCOS
Study NCT03352869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Use Metformin for 3 months to treat PCOS
Study NCT03034109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: TDCS involves sending a weak electrical current to the brain to modulate brain functions.
Study NCT02671552 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Ultrasound Imaging
Description: Undergo contrast-enhanced ultrasound imaging
Study NCT03034109 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: TDCS involves sending a weak electrical current to the brain to modulate brain functions.
Study NCT02785432 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham low level laser
Description: Sham laser will be administered using the same time and contact exposure as delivered for the active group, but without any energy delivered.
Study NCT02785432 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active low level laser
Description: Active treatment will be delivered using the time, contact, and energy exposures described in the arm description.
Study NCT01182987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dementia Care Management
Description: The SCAN Memory Program is a care management program for cognitively-impaired SCAN members and for their informal/family caregivers. The program includes collaboration between SCAN Health Plan, partnering medical groups, and community organizations.~Program activities include: 1) telephonic-structured assessments with informal caregivers conducted by SCAN Memory Program care managers; 2) problem identification as a result of these assessments; and 3) pre-established protocols and procedures for problem resolution.
Study NCT00897260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
Description: To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.~DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x~* Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x~* Fludarabine dose adjustment:~  70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight.~UCB Infusion